JD-5006 and JD-5037: Peripherally Restricted (PR) Cannabinoid-1 Receptor Blockers Related to SLV-319 (ibipinabant) As Metabolic Disorder Therapeutics Devoid of CNS Liabilities
Bioorganic & Medicinal Chemistry Letters（2012）
Key words
CB1 receptor inverse agonist,Metabolic disorders,Diabetes,Liver diseases,Dyslipidemias,Obesity,JD-5006,JD-5037,SLV-319,Peripherally restricted cannabinoid-1 receptor blockers,Rimonabant,CB1 antagonist
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined